1. Report Overview

1.1 Global Translational Regenerative Medicine: Market Overview

1.2 Global Translational Regenerative Medicine Market Definition and Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report for?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2. An Introduction to Translational Regenerative Medicine

2.1 What Is Regenerative Medicine?

2.1.1 Translational Regenerative Medicine – From Bench to Bedside

2.2 Translational Regenerative Medicine – Market Breakdown

2.2.1 Stem Cell Therapy – Marketable Differentiation and Specialisation

2.2.1.1 How Embryonic Stem Cells (ESCs) Entered the Fray

2.2.1.2 Classifying Stem Cells by Potency

2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs

2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?

2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?

2.2.2 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes

2.2.3 Gene Therapies

2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy

2.3 Other Approaches to Regenerative Medicine

2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules

2.3.2 Cosmetic Applications of Regenerative Medicine

2.4 Regulation of Regenerative Medicine

2.4.1 Regulation of Regenerative Medicine Products in Europe

2.4.2 Regulation of Regenerative Medicine Products in the US

2.5 The Phases of Clinical Trials

2.6 Market Definition

2.6.1 Products Excluded from the Report

3. Translational Regenerative Medicine Market, 2018-2028

3.1 Global Translational Regenerative Medicine: Market Overview

3.1.1 Segments within the Global Translational Regenerative Medicine Market

3.2 The Global Translational Regenerative Medicine Market in 2016 and 2017

3.3 Global Translational Regenerative Medicine: Market Forecast 2018-2028

3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth

3.3.2 Global Translational Regenerative Medicine Market - Changing Market Shares by Sector 2018-2028

3.3.3 Global Translational Regenerative Medicine Market – Current Developments in the Field, 2016 & 2017

3.3.4 Global Translational Regenerative Medicine Market – Current Advancement in the Field, 2016 & 2017

3.3.5 Global Translational Regenerative Medicine Market – Current Key Approvals in the Field, 2017

4. Stem Cell Therapies: Leading Applications, 2018-2028

4.1 The Global Market for Stem Cell Therapies, 2017 and 2018

4.1.1 Stem Cell Therapies: Currently Available Therapies

4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)

4.1.2.1 HSCT for the Treatment of Multiple Sclerosis – A Possible Cure?

4.1.3 Stem Cell Orthobiologics

4.2 Stem Cell Therapies: Global Market Forecast 2018-2028

4.3 AlloStem (AlloSource)

4.4 Osteocel Plus (NuVasive)

4.4.1 Osteocel Plus: Sales Forecast 2018-2028

4.5 Trinity ELITE and Trinity Evolution (Orthofix)

4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2018-2028

4.6 PureGen (AlphaTec Spine)

4.7 Other Approved Stem Cell Therapy Products

4.7.1 Cartistem (Medipost)

4.7.2 Cupistem (Anterogen)

4.7.3 Hearticellgram-AMI (Pharmicell)

4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)

4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2018-2028

4.8 Development Pipeline for Stem Cell Therapies, 2018-2028

4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2017

4.8.1.1 StemEx and NiCord (Gamida Cell)

4.8.1.1.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial

4.8.1.2 Copper Chelator Based Technology

4.8.1.3 NiCord

4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA

4.8.1.3.2 NAM Technology Platform

4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)

4.8.1.5 Adult Autologous CD34+ Cells (Baxter)

4.8.1.6 MyoCell (U.S. Stem Cell Inc.)

4.8.1.7 Adipocell (Bioheart)

4.8.1.8 Cx601 (TiGenix)

4.8.1.9 Adipose-Derived Stem Cells (Cytori Therapeutics)

4.8.1.10 Stempeucel (Stempeutics Research)

4.8.1.11 C-Cure (Cardio3 BioSciences)

4.8.1.12 Other Late-Stage Stem Cell Therapies

4.8.2 Diabetes and Stem Cell Therapy

4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)

4.8.2.2 VC-01 (ViaCyte Inc)

4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes

4.8.3 Cardiovascular Disease and Stem Cell Therapy

4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)

4.8.3.2 AMR-001 (Caladrius Biosciences)

4.8.3.3 CAP-1002 (Capricor)

4.8.4 Stem Cell Therapy in Cancer

4.8.4.1 CLT-008 (Cellerant Therapeutics)

4.8.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy

4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions

4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)

4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015

4.8.5.2 NSI-566 (Neuralstem)

4.8.5.3 NSI-189 (Neuralstem)

4.8.5.4 MultiStem (Athersys)

4.8.5.5 PDA-001 (Cenplacel-L, Celgene)

4.8.5.6 ALD-401 (Cytomedix)

4.8.5.7 ReN001 (ReNeuron)

4.8.6 Stem Cell Therapy for Eye Diseases

4.8.6.1 MA09-hRPE (Ocata Therapeutics)

4.8.6.2 HuCNS-SC (StemCells Inc.)

4.8.6.3 Collaboration and License Agreement Between Pfizer and the London Project to Cure Blindness

4.9 ChondroCelect (TiGenix BV)

4.10 Stem Cells Therapy Market: Drivers and Restraints 2018-2028

5. Tissue Engineering Therapies: Leading Applications, 2018-2028

5.1 The Global Market for Tissue Engineered Therapies, 2016

5.1.1 Tissue Engineering Therapies: Currently Available Therapies

5.2 Tissue Engineering Therapies: Global Market Forecast 2018-2028

5.3 Tissue Engineering in Wound Repair and Healing

5.3.1 Apligraf (Organogenesis)

5.3.1.1 Apligraf: Historical Sales Analysis

5.3.1.2 Apligraf: Sales Forecast 2018-2028

5.3.2 BioDfence and BioDfactor (BioD)

5.3.3 CureXcell (MacroCure)

5.3.4 Dermagraft (Organogenesis)

5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2018-2028

5.3.5 Epifix (MiMedx)

5.3.5.1 Epifix (MiMedx): Sales Forecast 2018-2028

5.3.6 Epicel (Vericel)

5.3.7 Grafix (Osiris Therapeutics)

5.3.8 MySkin and CyroSkin (Regenerys)

5.3.9 ReCell (Avita Medical)

5.3.9.1 ReCell (Avita Medical): Sales Forecast 2018-2028

5.4 Tissue Engineering for Cartilage Repair

5.4.1 Autologous Chondrocyte Implantation (ACI)

5.4.2 Carticel (Vericel Corp.)

5.4.3 ChondroCelect (TiGenix, Sobi Partners)

5.4.4 DeNovo NT (Zimmer)

5.4.5 MACI (Vericel Corp.)

5.5 Other Available Tissue Engineering Therapies

5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)

5.5.2 Gintuit (Organogenesis)

5.5.3 LAVIV (azficel-T), (Fibrocell Science)

5.5.4 Acellular Tissue Engineering Products

5.6 Tissue Engineering: Development Pipeline, 2018-2028

5.6.1 Pipeline Products for Autologous Chondrocyte Implantation

5.6.2 Tissue Engineering for Skin

5.6.3 Tissue Engineering for Liver Diseases

5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)

5.6.4 Tissue Engineering for Cardiovascular Disease

5.6.5 Tissue Engineering for Eye Diseases

5.7 Future Prospects for Organ Transplantation and Tissue Engineering

5.8 Tissue Engineered Products Market: Drivers and Restraints 2018-2028

6. Gene Therapies: Leading Applications, 2018-2028

6.1 The Global Market for Gene Therapies, 2017

6.2 Gene Therapies: Global Market Forecast 2018-2028

6.3 Currently Available Gene Therapy Products

6.3.1 Gendicine (Benda Pharmaceutical)

6.3.2 Oncorine (Shanghai Sunway Biotech)

6.3.3 Neovasculgen (Human Stem Cells Institute)

6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2018-2028

6.3.4 Glybera (UniQure)

6.3.4.1 Glybera: Sales Forecast 2018-2028

6.3.5 IMLYGIC (talimogene laherparepvec) – (Amgen)

6.3.5.1 Clinical Trials and Development Efforts for IMLYGIC

6.3.5.2 Talimogene Laherparepvec (IMLYGIC) – Sales Forecast 2018-2028

6.4 Development Pipeline for Gene Therapies, 2018-2028

6.4.1 Late-Stage Pipeline Gene Therapies, 2017

6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) - (AnGes MG/Vical)

6.4.1.2 ProstAtak (AdV-tk) - (Advantagene)

6.4.1.3 Trinam (taberminogene vadenovec) – (Ark Therapeutics)

6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)

6.4.1.5 CG0070 (Cold Genesys)

6.4.2 Gene Therapy for Use in the Treatment of Diabetes

6.4.3 Gene Therapy Directed at Oncology Indications

6.4.4 Gene Therapy Directed at Neurological Diseases

6.4.5 Gene Therapy Directed at Tackling Haemophilia B

6.5 Gene Therapy Market: Drivers and Restraints 2018-2028

7. Leading National Markets for Translational Regenerative Medicine, 2018-2028

7.1 The Translational Regenerative Medicine Market by Region

7.1.1 The Global Distribution of Translational Regenerative Medicine in 2017 and 2018

7.2 Leading National Markets: Forecast 2018-2028

7.2.1 Changing Market Shares by Region, 2018-2028

7.3 Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2018-2028

7.4 United States: The Largest Translational Regenerative Medicine Market

7.4.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2018-2028

7.4.2 US Translational Regenerative Medicine Market: Market Forecast 2018-2028

7.4.3 The Regulatory Framework for Regenerative Medicine in the US

7.4.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding

7.4.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?

7.5 Europe: A Fragmented Regenerative Medicine Market

7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2018-2028

7.5.2 European Regenerative Medicine Market: Market Forecast 2018-2028

7.5.3 Europe’s Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region

7.5.4 Regulation of Regenerative Medicine in the European Union

7.5.5 UK: A Leading Research Centre for Regenerative Medicine in Europe

7.5.5.1 Regulation of Stem Cell Research in the UK

7.5.6 Russia: Rising Interest in Regenerative Medicine Research

7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation

7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2018-2028

7.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2018-2028

7.6.3 Australia: Encouraging Translational Regenerative Medicine

7.6.4 China: Encouraging Stem Cell R&D

7.6.4.1 Government Intervention into TRM Research in China

7.6.4.2 Regulation of Stem Cell Research in China

7.6.4.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China

7.6.4.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China

7.6.5 Japan: Difficulty in Translating Research into Commercialisation

7.6.5.1 Research Funding: A Major Determinant of Growth in Japan’s Regenerative Medicine

7.6.5.2 Government Interventions in Promoting Stem Cell Research in Japan

7.6.5.3 Regulation of Regenerative Medicine in Japan

7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan

7.6.6 India: An Emerging Market for Regenerative Medicine

7.6.6.1 Efforts in Stem Cell Research in India

7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India

7.6.7 South Korea: First to Approve Stem Cell Treatments

7.6.7.1 A Regeneration in South Korea’s Stem Cell Research Efforts

7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming

7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2018-2028

8. Leading Companies in the Translational Regenerative Medicine Market, 2018-2028

8.1 Translational Regenerative Medicine: A Hotbed for Innovation

8.2 Alphatec Spine

8.2.1 Alphatec Spine: Financial and Performance Analysis, 2012-2016

8.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices

8.3 Anterogen

8.3.1 Anterogen: Pipeline Analysis, 2016

8.4 Athersys

8.4.1 Athersys: Financial and Performance Analysis, 2012-2017

8.4.2 Athersys: Pipeline Analysis, 2017

8.4.2.1 MultiStem Technology – Potential Treatment for a Range of Diseases

8.5 Avita Medical

8.5.1 Avita Medical: Historical Financial and Performance Analysis, 2013-2017

8.5.2 Avita Medical: Regenerative Medicine Portfolio, 2017

8.5.3 Avita Medical: Pipeline Analysis, 2017

8.6 AxoGen

8.6.1 AxoGen: Historical Financial and Performance Analysis, 2013-2017

8.6.2 AxoGen: Regenerative Medicine Portfolio, 2017

8.6.3 AxoGen: Pipeline Analysis, 2017

8.7 Medipost

8.7.1 Medipost: Historical Financial and Performance Analysis, 2013-2016

8.7.2 Medipost: Regenerative Medicine Portfolio, 2017

8.7.3 Medipost: Pipeline Analysis, 2017

8.8 Mesoblast

8.8.1 Mesoblast Product Portfolio, 2017

8.8.2 Mesoblast: Historical Financial and Performance Analysis, 2012-2017

8.8.3 Mesoblast: Pipeline Analysis, 2017

8.8.3.1 NeoFuse

8.8.3.2 Chondrogen

8.8.3.3 Prochymal / TEMCELL

8.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast

8.9 NuVasive

8.9.1 NuVasive Product Portfolio, 2017

8.9.2 NuVasive: Historical Financial and Performance Analysis, 2013-2017

8.9.3 NuVasive: Pipeline Analysis, 2017

8.10 Ocata Therapeutics (Acquired by Astellas Pharma Inc.)

8.10.1 Ocata Therapeutics: Historical Financial and Performance Analysis, 2013-2016

8.10.2 Ocata Therapeutics: Pipeline Analysis, 2017

8.10.2.1 Retinal Pigment Epithelial Cell Therapy

8.10.3 Ocata’s Other Therapeutic Platforms

8.11 Organogenesis

8.11.1 Organogenesis RM Portfolio, 2017

8.11.2 Organogenesis: Pipeline Analysis, 2017

8.12 Osiris Therapeutics

8.12.1 Osiris Therapeutics: RM Portfolio, 2017

8.12.2 Osiris Therapeutics: Historical Financial and Performance Analysis, 2011-2015

8.12.3 Osiris Therapeutics: Pipeline Analysis, 2015

8.13 Pharmicell

8.13.1 Pharmicell: Historical Financial and Performance Analysis, 2013-2016

8.13.2 Pharmicell: Pipeline Analysis, 2017

8.14 Regenerys

8.14.1 Regenerys: RM Portfolio, 2017

8.14.2 Regenerys: Pipeline Analysis, 2017

8.15 TiGenix

8.15.1 TiGenix: Historical Financial and Performance Analysis, 2013-2016

8.15.2 TiGenix: Pipeline Analysis, 2017

8.16 UniQure

8.16.1 UniQure: Recent Major Acquisition and Collaboration

8.16.2 UniQure: Pipeline Analysis, 2017

8.17 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)

8.17.1 Vericel’s Acquisition of Sanofi’s Regenerative Medicine Business

8.17.2 Vericel: Historical Financial and Performance Analysis, 2013-2017

8.17.3 Vericel Regenerative Medicine Portfolio, 2017

8.17.4 Vericel: Pipeline Analysis, 2017

8.17.4.1 The ixCELL-DCM Clinical Trial

9. Qualitative Analysis for the Global Translational Regenerative Medicine Market

9.1 Market Factors Influencing the Translational Regenerative Medicine Market

9.2 SWOT Analysis of the Translational Regenerative Medicine Market

9.3 Strengths

9.3.1 Improvements in Regulatory Frameworks

9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine

9.3.3 Strong Support from Governments in Multiple Regions

9.3.4 Increasing Ease of Product Commercialisation and Market Access

9.4 Weaknesses

9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth

9.4.2 Lack of Funding from Venture Capital

9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing

9.4.4 Successful Commercialisation of TRM Products Requires New Business Models

9.5 Opportunities

9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up

9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth

9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets

9.6 Threats

9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine

9.6.2 Difficulty Establishing Evidence Base for Long-Term Efficacy of TRM Therapies

9.6.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth

9.6.4 Restraints on Reimbursement May Slow Growth

9.7 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2018-2028

9.7.1 Threat of New Entrants

9.7.2 Threat of Substitutes

9.7.3 Power of Suppliers

9.7.4 Power of Buyers

9.7.5 Rivalry among Competitors

10. Conclusions

10.1 Overview of Current Market Conditions and Market Forecast, 2018-2028

10.2 Leading Regenerative Medicine Segments in 2017

10.3 Leading Regions in the Translational Regenerative Medicine Market 2017, 2022, 2028

10.4 Future Outlook for the Various Sectors within TRM, 2018-2028

10.5 R&D Pipeline Products Crucial to Future Market Growth

10.6 What Does the Future Hold for Regenerative Medicine?

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 2.1 European Union Definitions of Regenerative Medicine Products, 2017

Table 2.2 Potency and Source of Stem Cells, 2018

Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2018

Table 2.4 Major Types of Stem Cells and Their Properties, 2018

Table 2.5 Terminology for Stem Cell Donor-Types, 2018

Table 2.6 Clinical Trial Phases, 2018

Table 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2017 and 2018

Table 3.2 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2017-2022

Table 3.3 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2023-2028

Table 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2017-2022, 2023-2028 and 2017-2028

Table 3.5 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2017, 2022 and 2028

Table 3.6 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2017, 2022 a 2017

Table 6.13 Advantegene: Gene Therapy Clinical Trials, 2017

Table 6.14 Spark Therapeutics: Gene Therapy Clinical Trials, 2017

Table 6.15 Recent Developments in Gene Therapy for Use in Diabetes

Table 6.16 Gene Therapy Products in the Development Pipeline for Neurological Diseases, 2017

Table 7.1 The Global Translational Regenerative Medicine Market by Region: Market Size ($m) and Market Share (%) 2017 and 2018

Table 7.2 Global Translational Regenerative Medicine Market by Region: Market Forecast ($m), AGR (%) and CAGR (%), 2017-2022

Table 7.3 Global Translational Regenerative Medicine Market by Region: Market Forecast ($m), AGR (%) and CAGR (%), 2023-2028

Table 7.4 Global Translational Regenerative Medicine Market by Region: CAGR (%), 2017-2022, 2023-2028, 2017-2028

Table 7.5 Global Translational Regenerative Medicine Market by Region: Market Share (%), 2017, 2022 and 2028

Table 7.6 US Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2022 and 2028

Table 7.7 US Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022

Table 7.8 US Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028

Table 7.9 European Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2022 and 2028

Table 7.10 European Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022

Table 7.11 European Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028

Table 7.12 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017-2028

Table 7.13 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022

Table 7.14 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028

Table 7.15 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017-2028

Table 7.16 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022

Table 7.17 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028

Table 8.1 Alphatec Spine: Historical Sales ($m) and Operating Profit / Loss ($m), 2012-2016

Table 8.2 Alphatec Spine: Regenerative Medicine Clinical Trials, 2017

Table 8.3 Anterogen: Regenerative Medicine Clinical Trials, 2016

Table 8.4 Athersys: Historical Sales ($m) 2012-2017

Table 8.5 Athersys: Historical Expenditure and Losses ($m) 2012-2017

Table 8.6 Athersys: Regenerative Medicine Clinical Trials, 2017

Table 8.7 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2017

Table 8.8 Avita Medical: Regenerative Medicine Clinical Trials, 2017

Table 8.9 AxoGen: Historical Sales ($m) and Net Loss ($m), 2013-2017

Table 8.10 AxoGen: Regenerative Medicine Clinical Trials, 2017

Table 8.11 Medipost: Historical Sales ($m, mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2013-2016

Table 8.12 Medipost: Historical Sales (mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2013-2016

Table 8.13 Medipost: Regenerative Medicine Clinical Trials, 2017

Table 8.14 Mesoblast: Historical Sales ($m, AUD m), 2012-2017

Table 8.15 Mesoblast: Regenerative Medicine Clinical Trials, 2017

Table 8.16 NuVasive: Historical Sales ($m) and Net Income (Profits and Losses) ($m), 2013-2017

Table 8.17 NuVasive: Regenerative Medicine Clinical Trials, 2017

Table 8.18 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2013-2016

Table 8.19 Ocata Therapeutic: Regenerative Medicine Clinical Trials, 2017

Table 8.20 Organogenesis: Regenerative Medicine Clinical Trials, 2017

Table 8.21 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2011-2015

Table 8.22 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2015

Table 8.23 Pharmicell: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2011-2015

Table 8.24 Regenerys: Regenerative Medicine Clinical Trials, 2017

Table 8.25 TiGenix: Historical Sales (€m, $m) and Net Income (€m, $m), 2013-2016

Table 8.26 TiGenix: Regenerative Medicine Clinical Trials, 2017

Table 8.27 UniQure: Regenerative Medicine Clinical Trials, 2017

Table 8.28 Vericel: Historical Sales ($m and AGR%), 2013-2017

Table 8.29 Vericel: Sales by Product ($m) and Revenue Share (%), 2016-2017

Table 8.30 Vericel Corporation: Regenerative Medicine Clinical Trials, 2017

Table 9.1 SWOT Analysis of the Global Translational Regenerative Medicine Market

Table 10.1 Global Translational Regenerative Medicine: Market Forecast ($m, CAGR%), 2017, 2022, 2028

Table 10.2 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2017

Table 10.3 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Region, 2017, 2022 and 2028

Table 10.4 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2017, 2022 and 2028

Table 10.5 Global Translational Regenerative Medicine Market: Products in Late Stage Development, 2017

List of Figures

Figure 1.1 Global Translational Regenerative Medicine Market: Submarkets, 2018

Figure 2.1 Brief History of Stem Cell Research, 1900-2018

Figure 2.2 Examples of FDA-Approved Tissue Engineering Products

Figure 2.3 Brief History of Tissue Engineering, 1900-2018

Figure 2.4 Brief History of Gene Therapy, 1970-2018

Figure 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2017 and 2018

Figure 3.2 The Gene Therapy Market: Revenue ($m), 2017 and 2018

Figure 3.3 The Global Translational Regenerative Medicine Market Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2017-2022

Figure 3.5 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2023-2028

Figure 3.6 The Global Translational Regenerative Medicine Market Forecast:

CAGR (%) by Sector, 2017-2028

Figure 3.7 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2017, 2022 and 2028

Figure 3.8 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2017

Figure 3.9 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2022

Figure 3.10 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2028

Figure 4.1 Global Stem Cell Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 4.2 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 4.3 Trinity ELITE Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 4.4 TEMCELL / Prochymal Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 5.1 Global Tissue Engineering Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 5.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 5.3 Dermagraft Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 5.4 Epifix Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 5.5 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 5.6 Tissue Engineered Therapy Products: Drivers and Restraints

Figure 6.1 Global Gene Therapies Market Forecast: Revenue ($m) and AGR (%),2017-2028

Figure 6.2 Neovasculgen Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 6.3 Glybera Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 6.4 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 6.5 Gene Therapy Products: Market Drivers and Restraints

Figure 7.1 The Global Translational Regenerative Medicine Market by Region: Market Size ($m), 2017 and 2018

Figure 7.2 Global Translational Regenerative Medicine Market by Region: Market Forecast ($m), 2017-2028

Figure 7.3 Global Translational Regenerative Medicine Market by Region: CAGR (%), 2017-2022

Figure 7.4 Global Translational Regenerative Medicine Market by Region: CAGR (%), 2023-2028

Figure 7.5 Global Translational Regenerative Medicine Market by Region: CAGR (%), 2017-2028

Figure 7.6 Global Translational Regenerative Medicine Market by Region: Market Share (%), 2017

Figure 7.7 Global Translational Regenerative Medicine Market by Region: Market Share (%), 2022

Figure 7.8 Global Translational Regenerative Medicine Market by Region: Market Share (%), 2028

Figure 7.9 US Translational Regenerative Medicine: Market Drivers and Restraints

Figure 7.10 US Translational Regenerative Medicine Market Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 7.11 European Translational Regenerative Medicine: Market Drivers and Restraints

Figure 7.12 European Translational Regenerative Medicine Market Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 7.13 Asia-Pacific Translational Regenerative Medicine: Market Drivers and Restraints

Figure 7.14 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 7.15 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 8.1 Alphatec Spine: Historical Sales ($m) and Operating Loss ($m), 2012-2016

Figure 8.2 Athersys: Historical Sales ($m) 2012-2017

Figure 8.3 Athersys: Historical Revenue, Expenditure and Losses ($m) 2012-2017

Figure 8.4 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m), 2013-2017

Figure 8.5 AxoGen: Historical Sales ($m) and Net Loss ($m), 2013-2017

Figure 8.6 Medipost: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2013-2016

Figure 8.7 Medipost: Revenue Share by Business Area (%), 2016

Figure 8.8 Medipost: Revenue Share by Business Area (%), 2016

Figure 8.9 Medipost: Revenue Share by Business Area (%), 2016

Figure 8.10 Mesoblast: Historical Sales (AUD m), 2013-2017

Figure 8.11 NuVasive: Historical Sales and Net Income (Profits and Losses) ($m), 2013-2017

Figure 8.12 Ocata Therapeutics: Historical Sales ($m) and Gross Income ($thousand), 2013-2016

Figure 8.13 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2011-2015

Figure 8.14 Pharmicell: Historical Sales (mil.KRW) and Net Income (mil.KRW), 2013-2016

Figure 8.15 TiGenix: Historical Sales ($m) and Net Income ($m), 2013-2016

Figure 8.16 Vericel: Historical Sales ($m), 2013-2017 (Limited Scale)

Figure 8.17 Vericel: Revenue Contribution by Product (%) 2017

Figure 9.1 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2017

Figure 10.1 Global Translational Regenerative Medicine: Market Forecast ($m), 2017, 2022 and 2028

Figure 10.2 Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2017

Figure 10.3 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2017-2028